Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice

20 Feb 2018

Abstract excerpt

Anti-CTLA-4 monoclonal antibodies (mAbs) confer a cancer immunotherapeutic effect (CITE) but cause severe immunotherapy-related adverse events (irAE). Targeting CTLA-4 has shown remarkable long-term benefit and thus remains a valuable tool for cancer immunotherapy if the irAE can be brought under control. An animal model, which recapitulates clinical irAE and CITE, would be valuable for developing safer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29463898
DOI: 10.1038/s41422-018-0012-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized micePMID 29463898Read ↗

A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer targetSemantic proximity Read ↗

Lost in Translation: Deciphering the Mechanism of Action of Anti-human CTLA-4Semantic proximity Read ↗

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.Semantic proximity Read ↗

FcyRIIB is a novel immune checkpoint in the tumor microenvironment limiting activity of Treg-targeting antibodiesSemantic proximity Read ↗

Therapeutic gene editing of T cells to correct CTLA-4 insufficiencySemantic proximity Read ↗

Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy.Semantic proximity Read ↗

Manipulating T cell-mediated pathology: Targets and functions of monoclonal antibody immunotherapySemantic proximity Read ↗

TCR-independent killing of B cell malignancies by anti-third-party CTLs: the critical role of MHC-CD8 engagement.Semantic proximity Read ↗

Humanization of a strategic CD3 epitope enables evaluation of clinical T-cell engagers in a fully immunocompetent in vivo modelSemantic proximity Read ↗

The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell FunctionSemantic proximity Read ↗

Humanized Mice Reveal New Insights Into the Thymic Selection of Human Autoreactive CD8+ T CellsSemantic proximity Read ↗

In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.